Cardiovascular new drug Vascepa outcome trial REDUCE-IT reaches its main endpoint and multiple secondary endpoints

recently, Amarin Corporation announced the vassapent cardiovascular (CV) cardiovascular outcometheof the trial( the main results of which reached its main endpoint and multiple secondary endpointsstudies have also shown that Vascepa's mechanism of action is not related to the reduction of triglyceridesThe results of the REDUCE-IT study were also published in the New England Journal of MedicineVascepaVascepa capsule is a single-molecule prescriptionproduct(consisting of omega-3 fatty acids in the form of ethyl esters (commonly called EPA)Vascepa is not fish oil, but comes from fishIt isby theFDA (regulated manufacturing process), which effectively eliminates impurities, separates and protects monomolecular active ingredients from degradationVascepa (known as AMR101) has been designated as a new chemical entity by the FDAAmarin has been awarded a number ofpatentinternationally for its unique clinical characteristics of Vascepa 　　Vascepa lowers TG levels without raising LDL-C levels a global study on REDUCE-IT REDUCE-IT, 8,179 adult patients with statin (treated with a higher CV risk) participated in the trial results show that the main endpoint of implementation is to further reduce the relative risk of the first major adverse cardiovascular event (MACE) by 25% (HR, 0.75; 95% CI: 0.68-0.83; p 0.001), the key secondary endpoint of realization, the relative risk of cardiovascular death, non-fatal heart attack and non-stroke in the intended treatment population, and the relative risk of cardiovascular death, non-fatal heart attack and non-stroke in the intended treatment population, and the risk of cardiovascular death, non-fatal heart attack and non-stroke in the intended treatment population, further reduced by 25% (HR, 0.75; 95% CI: p 0.001) 0.74; 95% CI: 0.65-0.83; p 0.001 Other secondary endpoints include: 20% reduction in cardiovascular death risk, 31% reduction in risk of fatal or non-fatal heart attack, 28% reduction in risk of fatal or non-fatal stroke, 35% reduction in risk of acute or acute coronary artery rebuilding, and 32% reduction in hospitalization risk of unstable angina